Infusion von Daratumumab in Kombinationstherapien – Praktische Hinweise für den ambulanten Bereich

Abstract

Combination therapies such as Dara-Rd and Dara-Vd show significantly higher survival rates after 12 months than the respective therapies without Daratumumab. The initial infusion of Daratumumab is associated with a high incidence of IRR. Dosage and speed of infusion of Daratumumab have to be strictly controlled. Any suspicion of even low IRR requires corrections. Concomitant medication before and after Daratumumab administration is required. For this purpose, various preparations have been tested in everyday clinical practice. Eight hours of infusion may be required. This does not only overwhelm the patient, but also the most ambulant structures. The split-dose concept means to divide the dose into infusions on different days. Again, the dosage is crucial for good compatibility.

Daratumumab zeigt in klinischen Studien in Mono- und Kombinationstherapie eine Inzidenz der IRR aller Grade von 46 % bei Erstinfusion und von 2 – 3 % bei den anschließenden Infusionen (< 1 % mit IRR Grad 3). Diese Infusionsreaktionen machen Infusionspausen oder eine reduzierte Infusionsgeschwindigkeit erforderlich – und führen dadurch das Zeitmanagement ambulanter Therapiestationen und Praxen oft an ihre Grenzen.

Schlüsselwörter

Kombinationstherapie - IRR - multiples Myelom - Erstinfusion

Key words

combination therapy - IRR - multiple myeloma - intitial infusion

• Literatur

• 1 Lokhorst HM, Plesner T, Laubach JP. et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med 2015; 373 (13) 1207-1219
• 2 Lonial S, Weiss BM, Usmani SZ. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1551-1560
• 3 Dimopoulos MA, Oriol A, Nahi H. et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375 (14) 1319-1331
• 4 Palumbo A, Chanan-Khan A, Weisel K. et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375 (08) 754-766
• 5 Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc 2016; 91 (01) 101-119
• 6 Moreau P, van de Donk NWCJ, San Miguel J. et al. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs 2016; 76 (08) 853-856
• 7 Fachinformation Daratumumab. http://www.fachinfo.de/suche/daratumumab [2018-01-25]
• 8 Chari A, Mark TM, Krishnan A. et al. Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma ASH. 2016 Abstract 2142
• 9 Yimer H, Melear J, Faber E. et al. Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM). ASH. 2017 Abstract 1839
• 10 Lonial S, San-Miguel J, Martínez-Lopez J. et al. Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study. ASH. 2017 Abstract 1869
• 11 Chari A, Usmani SZ, Krishnan A. et al. Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study. ASH. 2017 Abstract 3110
• 12 Usmani SZ, Nahi H, Mateos MV. et al. Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO). ASH. 2016 Abstract 1149
• 13 Engelhardt M, Domm AS, Dold SM. et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 2017; 102: 2-13 http://www.myelomacomorbidityindex.org/de_calc.html
• 14 https://www.springer.com/de/book/9783662514191